U.S. FDA advisers back approval for Guardant's cancer test
23/05/2024 21:41
May 23 (Reuters) - Advisers to the U.S. Food and Drug
Administration on Thursday recommended for the approval of
Guardant Health's GH.O blood test to detect a cancer that
begins in the colon or rectum.
The panel voted seven-to-two in favor of benefits
outweighing risks when using the test called Shield for
colorectal cancer.
(Reporting by Puyaan Singh and Leroy Leo in Bengaluru; Editing
by Arun Koyyur)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers